Search

Your search keyword '"Laharie, David"' showing total 143 results

Search Constraints

Start Over You searched for: Author "Laharie, David" Remove constraint Author: "Laharie, David" Journal gastroenterology Remove constraint Journal: gastroenterology
143 results on '"Laharie, David"'

Search Results

1. Guselkumab in Patients With Moderately to Severely Active Ulcerative Colitis: QUASAR Phase 2b Induction Study

2. Guselkumab in Patients With Moderately to Severely Active Ulcerative Colitis: QUASAR Phase 2b Induction Study

3. Increasing Infliximab Dose Based on Symptoms, Biomarkers, and Serum Drug Concentrations Does Not Increase Clinical, Endoscopic, and Corticosteroid-Free Remission in Patients With Active Luminal Crohn’s Disease

5. Mo1565: EFFICACY AND SAFETY OF VEDOLIZUMAB IN PATIENTS WITH CHRONIC ACTIVE POUCHITIS REFRACTORY TO ANTI-TNF THERAPY: RESULTS OF A RETROSPECTIVE MULTICENTER STUDY

6. 887: WITHDRAWAL OF INFLIXIMAB OR ANTI-METABOLITE THERAPY IN CROHN'S DISEASE PATIENTS IN SUSTAINED REMISSION ON COMBINATION THERAPY: A RANDOMIZED UNBLINDED CONTROLLED TRIAL (SPARE)

7. Su1499: IMMUNOMODULATORS ARE PROTECTIVE AGAINST SEVERE COVID 19: RESULTS FROM A LARGE MULTICENTRE COHORT OF INFLAMMATORY BOWEL DISEASE PATIENTS

8. Tu1497: COMPARISON OF THE RISK OF CLINICAL RECURRENCE AFTER ILEOCOLONIC RESECTION FOR CROHN'S DISEASE FOR MODIFIED RUTGEERTS’ SCORE I2A AND I2B CATEGORIES: INDIVIDUAL PATIENT DATA META-ANALYSIS.

9. Mo1542: COMPARED EFFICACY OF USTEKINUMAB AND ANTI-TNF AGENTS AS FIRST-LINE BIOLOGICAL THERAPY IN LUMINAL CROHN’S DISEASE: A TWO-CENTER RETROSPECTIVE STUDY.

10. Tu1508: EFFICACY AND SAFETY OF INDUCTION THERAPY WITH CALCINEURIN INHIBITORS IN COMBINATION WITH USTEKINUMAN FOR ACUTE SEVERE COLITIS

11. Su1490: COVID-19: A PREVALENCE RATE TWO TIMES LOWER THAN THAT OF THE GENERAL POPULATION IN FRENCH PATIENTS WITH INFLAMMATORY BOWEL DISEASE TREATED WITH INTRAVENOUS BIOLOGIC AGENTS

12. Mo1481: CHANGES IN COLECTOMY FOR ULCERATIVE COLITIS DURING THE LAST TWO DECADES: AN IN-DEPTH RETROSPECTIVE ANALYSIS

15. 1179 PERSISTENCE, EFFICACY AND TOLERANCE OF SUBCUTANEOUS INFLIXIMAB AFTER SWITCH FROM INTRAVENOUS INFLIXIMAB IN IBD PATIENTS IN REMISSION:: ONE-TEAR RESULTS FROM A MULTICENTER PROSPECTIVE COHORT

16. 1176 EFFECTIVENESS AND SAFETY OF SUBCUTANEOUS INFLIXIMAB IN PERIANAL CROHN'S DISEASE: A MULTICENTRE COHORT STUDY

18. 985 EFFICACY OF MIRIKIZUMAB IN COMPARISON TO USTEKINUMAB IN PATIENTS WITH MODERATE-TO-SEVERE CROHN'S DISEASE: RESULTS FROM THE PHASE 3 VIVID 1 STUDY

20. Tu1768 PERSISTENCE OF SUBCUTANEOUS INFLIXIMAB AFTER SWITCHING FROM INTRAVENOUS IN A FRENCH NATIONAL COHORT OF IBD PATIENTS IN REMISSION

22. Sa1820 RISK OF INCIDENT CANCER IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE WITH PRIOR BREAST CANCER : A MULTICENTRE COHORT STUDY

23. 603 VEDOLIZUMAB PREVENTS POSTOPERATIVE REUCURRENCE IN CROHN'S DISEASE: RESULTS OF THE REPREVIO TRIAL

24. Deep Remission at 1 Year Prevents Progression of Early Crohn’s Disease

25. Su1912 CDEIS SCORE OF 2 IS OPTIMAL CUT-OFF ASSOCIATED WITH LOWER RISK OF DISEASE PROGRESSION IN EARLY CROHN'S DISEASE: DATA FROM THE CALM STUDY

26. Mo1873 WHICH SECOND-LINE BIOLOGIC AFTER ANTI-TNF FAILURE DURING CROHN'S DISEASE: USTEKINUMAB OR VEDOLIZUMAB, A MULTICENTRE RETROSPECTIVE STUDY

27. 946 DEEP REMISSION AT 1 YEAR IS NOT ASSOCIATED WITH BETTER OUTCOME IN CROHN'S DISEASE: LONG-TERM DATA FROM TAILORIX

29. Development and Validation of a Test to Monitor Endoscopic Activity in Patients With Crohn’s Disease Based on Serum Levels of Proteins

31. Tu1748 – Oral Curcumin is Not More Effective Than Placebo to Prevent Endoscopic Postoperative Recurrence in Patients with Crohn's Disease Treated with Concomitant Thiopurines: Results from a Randomized Controlled Trial

32. Mo1816 – Prediction of Endoscopic Activity in Patients with Crohn’s Disease – Systematic Review and External Validation of Published Prediction Models

33. 365 – Efficacy and Safety of Infliximab Retreatment in Luminal Crohn's Disease: A Multicentre, Prospective, Observational Cohort (Regain) Study

34. Sa1812 – Endoscopic and Deep Remission At 1 Year Prevents Disease Progression in Early Crohn's Disease: Long-Term Data from Calm

35. Reply

37. 600 - Endoscopy Based Therapeutic Management in Postoperative Recurrent Crohn's Disease: Results of a Multi-Center Retrospective Study

38. Mo1841 - Infliximab Exposure Predicts Superior Endoscopic Outcomes in Patients with Active Crohn's Disease: Pharmacokineticpharmacodynamic Analysis of Tailorix

39. Mo1785 - Long-Term Outcome of Crohn's Disease Complicated by Upper Gastrointestinal Stricture: A Getaid Cohort Study

41. Increasing Infliximab Dose Based on Symptoms, Biomarkers, and Serum Drug Concentrations Does Not Increase Clinical, Endoscopic, and Corticosteroid-Free Remission in Patients With Active Luminal Crohn’s Disease

43. Efficacy of Vedolizumab on Extraintestinal Manifestation in Patients with Inflammatory Bowel Diseases: A Post-Hoc Analysis of the Observ-IBD Cohort of the Getaid

45. Reply

47. Reply

48. 692 Drug-Level Based Dosing Versus Symptom-Based Dose Adaptation in Patients With Crohn's Disease: A Prospective, Randomized Multicenter Study (TAILORIX)

50. Tu1940 Patients' Point of View Regarding Acceptability and Usefulness of Inflammatory Bowel Diseases Monitoring Tools: Results From a Nationwide Multicenter Study (the ACCEPT Study)

Catalog

Books, media, physical & digital resources